HEMLIBRA® (Emicizumab-kxwh)

The FDA on October 4, 2018 approved HEMLIBRA® injection for prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (ages newborn and older) with Hemophilia A (congenital Factor VIII deficiency) with or without Factor VIII (FVIII) inhibitors. HEMLIBRA® is a product of Genentech, Inc.